Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

9.380 +0.210 (+2.29%)
Streaming Delayed Price Updated: 12:05 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 144,546
Open 9.170
Bid (Size) 9.380 (4)
Ask (Size) 9.410 (4)
Prev. Close 9.170
Today's Range 9.040 - 9.610
52wk Range 5.770 - 18.96
Shares Outstanding 70,679,395
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aclaris Therapeutics Earnings Perspective: Return On Capital Employed
 
Via Benzinga
Aclaris Therapeutics's Earnings Outlook
 
Via Benzinga

Performance

YTD
-37.76%
-37.76%
1 Month
+11.67%
+11.67%
3 Month
+32.67%
+32.67%
6 Month
-40.06%
-40.06%
1 Year
-36.41%
-36.41%

More News

Read More
3 Biotech Stocks to Sell Before They’re 6 Feet Under
Via InvestorPlace
(ACRS) - Analyzing Aclaris Therapeutics's Short Interest
Via Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Analyst Ratings for Aclaris Therapeutics
Via Benzinga
Why Aclaris Therapeutics Is Crashing Today
Via The Motley Fool
Why Aclaris Therapeutics Stock Is Plunging Today
Via Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Aclaris Therapeutics's Return On Capital Employed Insights
Via Benzinga
Looking Into Aclaris Therapeutics's Return On Capital Employed
Via Benzinga
These 2 Biotech Stocks Made Big Monday Moves
Via The Motley Fool
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
Via Benzinga
As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
Via Benzinga
Nasdaq Rises 50 Points; US Factory Orders Down 1.6% In January
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal
Via Talk Markets
10 Best Stocks to Buy Now in December
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.